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Abstract 
Background: Ovarian reserve is defined as the existent quantitative and qualitative supply of follicles which are 
found in the ovaries that can potentially develop into mature follicles which in effect determines a woman’s 
reproductive potential. Many tests of ovarian reserve are employed including clinical, endocrine static, endocrine 
dynamic and  ultrasonographic markers. 
Aims of study: To determine the age-related changes in AMH and IGF-1 levels that occurs in Iraqi women as 
markers of ovarian reserve and to determine the specificity and sensitivity of IGF-1 and FSH for ovarian reserve. 
Subjects, material and methods:  One hindered cases were collected dividing into two groups; first group 
includes fifty cases of child bearing age, healthy, fertile females with regular menstrual cycle while second group 
includes fifty cases of postmenopausal aging group, healthy with normal fertility history. Serum levels of 
Follicle stimulating hormone, Luteinizing hormone, Prolactin, Anti Müllerian Hormone and Insulin like Growth 
Factor-1 were estimated for all cases.          
Results: The overall mean age of the respondents was 45.06 ± 16.68 years old with significant statistical 
difference between the mean age of pre and post-menopausal women. Results of Anti Müllerian Hormone 
showing a significant statistical difference between means of Anti Müllerian Hormone hormone for pre-
menopausal women (2.89± 2.07 ng/ml) and post-menopausal women (0.0± 0.0 ng/ml). Measuring of Insulin like 
Growth Factor-1 showing significant statistical difference between pre-menopausal women (211.04± 63.81 
ng/ml) and post-menopausal groups' women (120.70± 39.69 ng/ml). Similarly results of Follicle stimulating 
hormone reveal significant differences between means of Follicle stimulating hormone for pre-menopausal 
women (6.03± 1.53 ml U/ ml) and post-menopausal women (56.06± 17.07 ml U/ ml). There was no significant 
association between AMH and IGF1 hormones and IGF1 hormone has been failed to detect ovarian reserve and 
still the AMH is the gold standard test. 
Conclusion: Significant changes occur in Anti Müllerian Hormone, I Insulin like Growth Factor-1  and Follicle 
stimulating hormone with progression of the age and Anti Müllerian Hormone still the stander ovarian reserve 
test in compare with Insulin like Growth Factor-1 and Follicle stimulating hormone.    
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Introduction 
Ovarian reserve is defined as the existent quantitative and qualitative supply of follicles which are found in the 
ovaries that can potentially develop into mature follicles which in effect determines a woman’s reproductive 
potential [1]. The commonly employed tests of ovarian reserve are: Clinical markers (like age and menstrual 
pattern), endocrine static markers (as estradiol, FSH, Inhibin-B, and AMH), endocrine dynamic markers and  
ultrasonographic markers [2]. 
Basal FSH is the most widely used test to assess ovarian reserve. It is secreted by the anterior pituitary and acts 
on the receptors expressed by the granulosa cells of gonadotrophin responsive antral follicles. Increasing levels 
of basal FSH is the earliest sign of human reproductive aging [3]. The measurement of FSH in the early 
follicular phase of the menstrual cycle is an accurate indicator of ovarian function but is not a good predictor of 
time remaining to menopause [4]. 
Journal of Biology, Agriculture and Healthcare                                                                                                                                www.iiste.org 
ISSN 2224-3208 (Paper)  ISSN 2225-093X (Online) 
Vol.4, No.4, 2014 
 
98 
AMH is expressed by the granulosa cells of the early growing, pre-antral and small antral follicles, but not by 
non-atretic, larger antral follicles or those that have become atretic, and may reflect or represent the population 
of smaller antral follicles more than the overall number [5,6]. The production of AMH starts following follicular 
transition from the primordial to the primary stage, and it continues until the follicles reach the antral stages, 
with diameters of 2-6 mm [6]. AMH acts as a paracrine rather than a systemic factor, and thus is not part of a 
negative feedback loop with involvement of gonadotropins. AMH is not influenced by the gonadotropic status 
and reflects only the follicle population [7]. The biological role of AMH is still unclear, but rodent data suggest 
that it acts as a modulator of follicle recruitment and ovarian steroidogenesis [8].  It inhibits recruitment of 
follicles from the primordial pool by modifying the FSH sensitivity of those follicles [7]. 
Growth hormone is made in the anterior pituitary gland, is released into the blood stream, and then stimulates the 
liver to produce IGF-1. IGF-1 then stimulates systemic body growth, and has growth-promoting effects on 
almost every cell in the body. IGF-I has stimulatory effects on cartilage growth, hematopoiesis, ovarian 
steroidogenesis, myoblast proliferation and differentiation, and many other body tissues [9]. Granulosa cells of 
several species possess receptors for IGFs and respond to IGFs; several endpoints related to growth and 
differentiations are stimulated. Ovarian follicular fluid contains abundant quantities of IGFs [10]. 
Menopause is defined as the permanent cessation of menstruation resulting from the loss of ovarian follicular 
activity [11]. 
Reproductive ageing is thought to be due to a gradual decrease in both the quantity and quality of the oocytes 
contained within the follicles present in the ovarian cortex [12].  With the decline in the number of primordial 
follicles, oocyte quality also diminishes, especially after the age of 31 years, when fecundity gradually starts to 
decrease. Several factors might be responsible for this age related decline in the quality of oocytes. These may 
relate to differences between germ cells at the time they are formed during foetal life, damage to oocytes during 
the course of a woman’s life or changes in the quality of granulosa cells surrounding the primordial follicles 
[12]. Impaired perifollicular microcirculation resulting in low oxygen levels and a concomitant increase in 
anaerobic products in the follicular fluid [13]. Also, endocrine imbalance caused due to increase in levels of FSH 
and altered FSH: LH ratio is associated with decline in oocytes quality [14]. 
Subjects, material and methods 
This study was conducted in the city of Karbala, from November 2012 to August 2013. All cases were collected 
at different sites depending on available data of age and fertility status, including Teaching Hospital for 
Gynecology and Obstetrics, Al-Hussain Teaching Hospital and own relatives. The practical side of the study was 
performed at the laboratory of clinical biochemistry department in College of Medicine / Babylon University and 
in Al-Hussain Teaching Hospital in Karbala. 
This study was including 100 cases dividing into two groups; First group includes fifty cases of child bearing 
age, healthy, fertile females, and regular menstrual cycle with mean age (29.84 ± 6.66 years) while Second group 
includes fifty cases of postmenopausal aging group, healthy, normal fertility history with mean age (60.28 ± 
6.74). 
 About five milliliters of venous blood was aspirated and  sera were  separated  and  divided  into  5 parts  in 
labeled  eppindorf  tubes and given a serial  number  together  with  the  patients  names  then  frozen at  –20 0C  
until  time  of  usage. 
Five parameters were estimated for all cases. FSH, LH and PRL were estimated using VIDAS technique 
(BioMerieux/France) with principle of combines an enzyme immunoassay sandwich method with a final 
fluorescent detection (ELFA). AMH estimated by ELISA technique (BioTek  /USA) while IGF-1 estimated by 
LIAISON (DiaSorin S.P.A. Italy) for with one step sandwich CLIA (Chemiluminescence Immunoassay). 
 
Data Analysis 
Statistical analysis was carried out using SPSS version 18. Categorical variables were presented as frequencies 
and percentages. Pearson’s chi square (X2) test and fisher exact test were used to find the association between the 
categorical variables. ROC test was used to find the accuracy of using IGF1 as well as with FSH to detect 
ovarian reserve. Independent sample t-test was used to compare means between two groups. A p-value of ≤ 0.05 
was considered as significant. 
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Result and discussion: 
Distribution of Age: The overall mean age of the respondents was 45.06 ± 16.68 years old. There was 
significant statistical difference between the mean age of pre-menopausal women (29.84 ± 6.66 years) and the 
mean age of post-menopausal women (60.28 ± 6.74). This difference certainly related to the design of study 
regarding cases selection of both pre and post-menopausal age groups. 
It is well understood that the ovarian follicular pool and hence fertility declines with age [17]. Age must always 
be the first marker to be considered in ovarian reserve assessment. Older women may benefit from ovarian 
reserve tests since they can help clinicians to find out acceptable chances of pregnancy through IVF [4]. 
Distribution of AMH: Results of AMH showing a significant statistical difference between means of AMH 
hormone for pre-menopausal women (2.89± 2.07 ng/ml) and post-menopausal women (0.0± 0.0 ng/ml). This 
statistical difference mostly related to normal physiological expression of AMH by granulosa cells of follicles in 
pre-menopausal period which start to diminish until their absence at menopausal age level [5]. 
Distribution of IGF1: Production of IGF-1 is stimulated by growth hormone which is produced throughout life. 
The highest rates of IGF-1 production occur during the pubertal growth spurt. The lowest levels occur in infancy 
and old age. Granulosa cells of several species possess receptors for IGFs and respond to IGFs [18]. These facts 
mostly explain the findings of the statistical difference in IGF-1 levels between pre-menopausal women 
(211.04± 63.81 ng/ml) and post-menopausal groups' women (120.70± 39.69 ng/ml).  
Distribution of FSH: There were significant differences between means of FSH for pre-menopausal women 
(6.03± 1.53 ml U/ ml) and post-menopausal women (56.06± 17.07 ml U/ ml). These  differences in statistical 
results are related to normal hormonal balance in pre-menopausal age of FSH level controlled by negative 
feedback of inhibin B and E2 which are produced by ovarian follicles while absence of such feedback lead to 
high FSH level in post-menopausal female [19]. 
Association of AMH with IGF1: There was no significant association between AMH and IGF1 hormones p = 
1.000 (table 2). The sensitivity of IGF1 hormone to detect ovarian reserve was (49.5%), meanwhile, its 
specificity was (33.3%). The positive predictive value was (96.0%) that means 96% of ovarian reserve likely to 
have IGF1 hormone ≥ 150 ng/ ml, meanwhile, the negative predicative value was (6.0%), which means that the 
ovarian reserve unlikely to have IGF1 hormone < 150 ng/ ml.  
These findings are consisting with many other studies regarding predictive value of AMH which showing that 
AMH is the best predictive factor for ovarian reserve despite many dynamic and static markers are still use, as 
studies of V.S Kalaiselvi et al (2012) and Ficicioglu et al (2006). The ROC curve has been done to determine the 
accuracy of IGF1 hormone in detecting the ovarian reserve comparing by AMH as in table 3. The accuracy of 
the test depends on how well the test separates the group being tested into those with and without the disease. 
Accuracy is measured by the area under the ROC curve. An area of one represents a perfect test; an area of 0.5 
represents a worthless test. Table 3 shows that the area under the curve is 0.414, means that the IGF1 hormone 
has been failed to detect ovarian reserve and still the AMH is the gold standard test 
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Table 1: Mean differences of AMH, IGF-1 and FSH by pre and post-menopausal women 
    
Parameter  N Mean S.D t-test P value 
 
AMH 
 
Pre-Menopausal women  50 
 
2.89 
 
2.07 9.891 <0.001* 
Post-Menopausal women  50 
 
0.0 
 
0.0 
IGF-1 
Pre-Menopausal women  50 211.04 63.81 8.500 <0.001* 
Post-Menopausal women  50 120.70 39.69 
FSH 
Pre-Menopausal women  50 6.03 1.53 20.644 <0.001* 
Post-Menopausal women  50 56.06 17.07 
 
Table 2: Association of AMH with IGF1  
P values 
AMH 
Variable 
 
Total 
 
> 6.5 ng/ml (%) 
 
≤ 6.5 ng/ ml (%) 
 
 
1.000 * 
 
50 (50.0) 
50 (50.0) 
100 (100) 
 
2 (66.7) 
1 (33.3) 
3 (100.0) 
 
48 (49.5) 
49 (50.5) 
97 (100.0) 
 
IGF1 
≥ 150 ng/ ml 
< 150 ng/ ml 
Total 
 
Table 3: Area under the curve for detecting ovarian reserve by IGF1 comparing by AMH: 
 
Area 
 
Std. Error P value 95% CI 
0.414  0.163 0.613 
Lower Bound Upper Bound 
 
0.095 
 
0.734 
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